RESUMEN
We demonstrate for the first time the appearance of acyclovir resistance in serial varicella zoster isolates from a patient treated with acyclovir. We recovered varicella zoster virus three times over a period of 5 months from the skin lesions of this patient with AIDS who was treated with three courses of intravenous acyclovir and prolonged low-dose oral acyclovir. The isolate recovered from a typical zoster lesion before acyclovir, and one obtained from a hyperkeratotic lesion 2 months later, after intravenous and oral acyclovir, were sensitive to acyclovir and produced normal amounts of thymidine kinase. In contrast, virus recovered from lesions 5 months after the onset, when the patient had received repeated courses of acyclovir, was acyclovir-resistant and thymidine-kinase-deficient. Resistance to acyclovir was associated with persistence of lesions which failed to improve with intravenous acyclovir, but was not associated with new lesion formation.
Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/tratamiento farmacológico , Aciclovir/farmacología , Herpesvirus Humano 3/efectos de los fármacos , Síndrome de Inmunodeficiencia Adquirida/complicaciones , Síndrome de Inmunodeficiencia Adquirida/patología , Aciclovir/uso terapéutico , Adulto , Farmacorresistencia Microbiana , Femenino , Herpes Zóster/complicaciones , Herpes Zóster/tratamiento farmacológico , Herpes Zóster/patología , Humanos , Timidina Quinasa/metabolismoRESUMEN
The sensitivity of varicella zoster virus (VZV) strain Ellen to acyclovir in combination with other antiherpetic agents in vitro has been examined by the plaque-reduction and infectious center assay methods. (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), trifluorothymidine (TFT), or 5-iodo-2'-deoxyuridine (IdUrd) produced, in general, additive antiviral activity when examined by either assay method. Acyclovir in combination with phosphonoacetate (PAA) resulted in additive effects as measured by the plaque-reduction assay. The combination of acyclovir with 9-beta-D-arabinofuranosyladenine (ara-A) gave generally additive or occasionally synergistic antiviral activity when tested in MRC-5 or WI-38 cells respectively, regardless of assay method.
Asunto(s)
Antivirales/farmacología , Herpesvirus Humano 3/efectos de los fármacos , Aciclovir , Bromodesoxiuridina/análogos & derivados , Bromodesoxiuridina/farmacología , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Sinergismo Farmacológico , Guanina/análogos & derivados , Guanina/farmacología , Idoxuridina/farmacología , Trifluridina/farmacología , Ensayo de Placa ViralRESUMEN
A series of acyclovir-resistant mutants of varicella zoster virus (VZV) were selected in vitro by serial passage of VZV-infected human fibroblasts in increasing drug concentrations, or by continuous exposure of cultures infected at high multiplicity to 100 microM acyclovir. The in vitro susceptibility of these mutants to several antiherpetic agents was measured by the plaque-reduction assay. The capacity of extracts of cells infected with these mutants to phosphorylate acyclovir was examined and compared with that of their acyclovir-sensitive parent strains. Based on these studies, VZV could be shown to acquire resistance to acyclovir through diminished acyclovir phosphorylation. This was presumable due to loss of viral specific thymidine kinase (TK) function. Two acyclovir-resistant mutants remained TK competent but demonstrated phenotypic changes in sensitivity to antiviral agents known to act at the herpes simplex virus (HSV)-specific DNA polymerase level. These results suggest that the resistance of VZV to acyclovir results from qualitative or quantitative alterations in the virus-specified TK or DNA polymerase.
Asunto(s)
Antivirales/farmacología , Guanina/análogos & derivados , Herpesvirus Humano 3/efectos de los fármacos , Aciclovir , ADN Polimerasa Dirigida por ADN/metabolismo , Farmacorresistencia Microbiana , Guanina/metabolismo , Guanina/farmacología , Herpesvirus Humano 3/enzimología , Herpesvirus Humano 3/genética , Mutación , Fosforilación , Timidina Quinasa/metabolismoRESUMEN
Acyclovir inhibited the replication of a varicella-like simian virus (DHV-1) in cell culture (Vero cells) with an ED50 of 38 +/- 2 microM. The activation of acyclovir in this cell culture system was compared with that in the cell system with human varicella zoster virus (VZV). Extracts of cells infected with DHV-1 catalyzed the phosphorylation of acyclovir. The phosphorylation was inhibited by dThd, suggesting the catalyst was a dThd kinase. Electrophoresis of cytosol fractions on polyacrylamide gels corroborated the existence of a virus-associated dThd kinase. This enzyme copurified with an acyclovir-phosphorylating activity. The enzyme catalyzed the phosphorylation of acyclovir at a greater relative rate than that with the VZV enzyme, but with a higher apparent Km value for acyclovir. The relative efficiencies for the two enzymes with acyclovir were similar. Anabolic studies with cells infected with DHV-1 and incubated with [14C]acyclovir indicated that triphosphate of acyclovir did accumulate. The results indicate that acyclovir is activated in cells infected with DHV-1 in a manner similar to that in cells infected with VZV.
Asunto(s)
Antivirales/farmacología , Guanina/análogos & derivados , Herpesviridae/efectos de los fármacos , Aciclovir , Animales , Línea Celular , Chlorocebus aethiops , Guanina/metabolismo , Guanina/farmacología , Herpesviridae/enzimología , Herpesvirus Humano 3/efectos de los fármacos , Cinética , Fosforilación , Timidina Quinasa/metabolismoRESUMEN
A series of pyrimidines related to the potent antiherpetic agent 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine (1, BW B759U), all containing the same acyclic chain, have been synthesized. Some of the compounds were derivatives of the naturally occurring bases, cytosine, uracil, and thymine; others included compounds in which the 5-position of the cytosine and uracil moieties were substituted by bromo, iodo, fluoro, methyl, and amino groups. Other variations of the cytosine derivatives were the 5-aza, 2-mercapto, 4-methylamino, 4-dimethylamino, and isocytosine congeners. A 4-aminopyrimidine adduct was also made. Antiviral testing showed that 1-[(1,3-dihydroxy-2-propoxy)methyl]cytosine (18, BW A1117U) was equivalent to the guanine analogue in potency against human cytomegalovirus and Epstein Barr virus. Other compounds in the series were largely inactive in antiviral screening against the herpesviruses.
Asunto(s)
Aciclovir/análogos & derivados , Antivirales/síntesis química , Citomegalovirus/efectos de los fármacos , Herpesvirus Humano 4/efectos de los fármacos , Pirimidinas/síntesis química , Aciclovir/síntesis química , Aciclovir/farmacología , Línea Celular , Células Cultivadas , Citomegalovirus/genética , Genes Virales/efectos de los fármacos , Herpesvirus Humano 4/genética , Humanos , Indicadores y Reactivos , Espectroscopía de Resonancia Magnética , Pirimidinas/farmacología , Relación Estructura-ActividadRESUMEN
The racemic isosteric phosphonate of ganciclovir monophosphate (BW2482U89, SR3745, [3-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-4- hydroxybutyl]phosphonic acid, 1) has potent and selective in vitro activity against human cytomegalovirus. An enantiospecific synthesis of the R-enantiomer of compound 1 starting from L-arabinose was developed. The synthesis involved (1) the preparation of a chiral acyclic moiety, (2) the coupling of the chiral acyclic moiety to diacetylguanine, (3) the introduction of phosphorus, and (4) the final deprotection. The R-enantiomer, which has stereochemistry analogous to the natural compound GMP, was tested against human cytomegalovirus and had an IC50 of 1.7 microM, which was approximately 2-fold more active than the racemic material. Both racemic and chiral compounds were less toxic than ganciclovir to bone marrow progenitor cells in an in vitro assay.
Asunto(s)
Antivirales/síntesis química , Citomegalovirus/efectos de los fármacos , Ganciclovir/análogos & derivados , Guanina/análogos & derivados , Antivirales/farmacología , Células de la Médula Ósea , Ganciclovir/síntesis química , Ganciclovir/farmacología , Ganciclovir/toxicidad , Guanina/síntesis química , Guanina/farmacología , Guanina/toxicidad , Guanosina Monofosfato/química , Células Madre Hematopoyéticas/efectos de los fármacos , Humanos , Espectroscopía de Resonancia Magnética , Estructura Molecular , Fósforo/química , EstereoisomerismoRESUMEN
An enzyme that catalyzes the conversion of CDP to 2'-dCDP in the presence of dithiothreitol (DTT) was detected in ammonium sulfate fractionated-extracts of varicella zoster virus (VZV)-infected cells. This ribonucleotide reductase was antigenically distinguishable from the isofunctional eucaryotic enzyme as well as the ribonucleotide reductases induced by herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). The VZV-induced enzyme was purified to the extent that most of the contaminating enzymes, which would significantly deplete the substrate, were removed. The VZV-induced ribonucleotide reductase exhibited maximum activity in the absence of ATP and/or magnesium and was only weakly inhibited by 2'-deoxynucleoside triphosphates. Furthermore, ADP, UDP and GDP competitively inhibited CDP reduction with Ki (Km) values of 15, 20, 1.8 and 0.88 microM, respectively. These kinetic properties were very similar to those of the correspondingly purified ribonucleotide reductases induced by HSV-1 [Averett et al., J. biol. Chem. 258, 9831 (1983)] and HSV-2 [Averett et al., J. Virol. 52, 981 (1984)] and were dissimilar to the allosterically regulated mammalian enzyme. A723U, an inactivator of HSV-1 ribonucleotide reductase that potentiates the anti-HSV-1 activity of acyclovir [Spector et al., Proc. natn. Acad. Sci. U.S.A. 82, 4254 (1985)], also appeared to inactivate this VZV-induced ribonucleotide reductase and to potentiate the anti-VZV activity of acyclovir.
Asunto(s)
Aciclovir/farmacología , Varicela/enzimología , Herpesvirus Humano 3/enzimología , Piridinas/farmacología , Ribonucleótido Reductasas/biosíntesis , Tiosemicarbazonas/farmacología , Células Cultivadas , Varicela/tratamiento farmacológico , Citidina Difosfato/metabolismo , Sinergismo Farmacológico , Inducción Enzimática , Herpesvirus Humano 3/efectos de los fármacos , Herpesvirus Humano 3/crecimiento & desarrollo , Humanos , Técnicas Inmunológicas , Cinética , Ribonucleótido Reductasas/antagonistas & inhibidores , Ribonucleótido Reductasas/aislamiento & purificación , Replicación Viral/efectos de los fármacosRESUMEN
PURPOSE: Cytomegalovirus retinitis is the most common intraocular infection in patients with acquired immunodeficiency syndrome (AIDS). With prolonged suppressive anticytomegalovirus maintenance therapy, resistance occurs in over 25% of patients. We evaluated longitudinal changes in the cytomegalovirus genotype in patients with cytomegalovirus retinitis who developed ganciclovir resistance that was demonstrated in either the blood or urine. METHODS: Patients with AIDS and previously untreated cytomegalovirus retinitis were followed prospectively for the occurrence of resistance while on treatment. Blood and urine specimens were obtained periodically for cytomegalovirus culture according to a predetermined schedule. Positive isolates were tested for phenotypic susceptibility and for mutations in the UL97 and UL54 genes. RESULTS: A mutation conferring resistance to ganciclovir in either the UL97 or UL54 gene was detected in 18 patients. In general, patients with a genotypically resistant virus developed increasing phenotypic resistance over time. There was a suggestion that unless therapy was changed, UL97 mutations tended to persist. In seven of eight patients, the mutations identified in isolates from the blood and urine were identical. In selected patients, there was a suggestion that a mixed population of cytomegalovirus might be present. Progression of the retinitis in an involved eye (15 of 18), contralateral eye retinitis (10 of 11), and extraocular cytomegalovirus disease (5 of 18) occurred commonly among patients with resistant virus. CONCLUSION: Resistance-conferring mutations in the cytomegalovirus genome emerge and may persist when the selective pressure for resistance is maintained. Some patients appear to harbor complex subpopulations of virus with different mutations and different levels of phenotypic resistance. Changes in therapy may result in a shift in virus population and changes in the cytomegalovirus genotype identified.
Asunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/virología , Antivirales/farmacología , Retinitis por Citomegalovirus/virología , Citomegalovirus/efectos de los fármacos , Ganciclovir/farmacología , Mutación , Proteínas Virales , Adulto , Anciano , Sangre/virología , Estudios de Cohortes , Citomegalovirus/genética , Citomegalovirus/aislamiento & purificación , ADN Viral/análisis , ADN Polimerasa Dirigida por ADN/genética , Farmacorresistencia Microbiana , Femenino , Genotipo , Humanos , Masculino , Persona de Mediana Edad , Fosfotransferasas (Aceptor de Grupo Alcohol)/genética , Estudios Prospectivos , Orina/virologíaRESUMEN
The AD169 strain of human cytomegalovirus was approximately twofold more sensitive to polyhalogenated benzimidazole ribonucleosides than Towne strain. Sequence differences between the two strains have been identified in genes UL51, UL52, UL56, UL77, UL89 and UL104. Because these genes are involved in cleavage and packaging of viral DNA and the benzimidazole ribonucleosides inhibit this process, these sequence differences may be involved in the difference in drug sensitivity.
Asunto(s)
Bencimidazoles/química , Citomegalovirus/fisiología , Ribonucleósidos/farmacología , Ensamble de Virus/genética , Citomegalovirus/genética , Genes Virales , Datos de Secuencia Molecular , Ribonucleósidos/químicaRESUMEN
A racemic mixture of ganciclovir phosphonate was resolved by stereoselective phosphorylation using GMP kinase. The R-enantiomer of ganciclovir phosphonate was active against human cytomegalovirus but the S-enantiomer was less active. We show that enantiomeric selectivity of antiviral for ganciclovir phosphonate was conferred by stereoselective phosphorylations by mammalian enzymes, not by stereoselective inhibition of DNA polymerase from human cytomegalovirus.
Asunto(s)
Antivirales/química , Citomegalovirus/efectos de los fármacos , Ganciclovir/análogos & derivados , Nucleósido-Fosfato Quinasa/química , Antivirales/aislamiento & purificación , Antivirales/metabolismo , Antivirales/farmacología , Línea Celular , Ganciclovir/química , Ganciclovir/aislamiento & purificación , Ganciclovir/metabolismo , Ganciclovir/farmacología , Guanilato-Quinasas , Humanos , Inhibidores de la Síntesis del Ácido Nucleico , Nucleósido-Fosfato Quinasa/metabolismo , Fosforilación , Fosfotransferasas (Aceptor de Grupo Alcohol)/metabolismo , Estereoisomerismo , Relación Estructura-ActividadRESUMEN
A series of 2'-deoxy analogues of the antiviral agent 5,6-dichloro-2-isopropylamino-1-(beta-L-ribofuranosyl)-1H-benzimidazole (1263W94) were synthesized and evaluated for activity against human cytomegalovirus (HCMV) and for cytotoxicity. The 2-substituents in the benzimidazole moiety correspond to those that were used in the 1263W94 series. In general, as was found in the 1263W94 series, cyclic and branched alkylamino groups were needed for potent activity against HCMV. Three analogues 3a, 3b and 3d were as potent as 1263W94. Further evaluation of two analogues, 3a and 3b, suggested that these 2'-deoxy analogues may act via a novel mechanism of action similar to that of 1263W94. These 2'-deoxy analogues generally lacked cytotoxicity in vitro. Pharmacokinetic parameters in mice and protein binding properties of 3a were quite similar to 1263W94. However, the oral bioavailability of 3a was only half of that observed for 1263W94.
Asunto(s)
Antivirales/síntesis química , Bencimidazoles/síntesis química , Citomegalovirus/efectos de los fármacos , Ribonucleósidos/síntesis química , Animales , Antivirales/química , Antivirales/farmacocinética , Antivirales/farmacología , Bencimidazoles/química , Bencimidazoles/farmacocinética , Bencimidazoles/farmacología , Disponibilidad Biológica , Células Cultivadas , Humanos , Espectroscopía de Resonancia Magnética , Masculino , Ratones , Ratones Endogámicos , Ribonucleósidos/química , Ribonucleósidos/farmacocinética , Ribonucleósidos/farmacologíaAsunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/virología , Antivirales/farmacología , Retinitis por Citomegalovirus/virología , Citomegalovirus/efectos de los fármacos , Ganciclovir/farmacología , Mutación Puntual , Infecciones Oportunistas Relacionadas con el SIDA/tratamiento farmacológico , Citomegalovirus/genética , Citomegalovirus/aislamiento & purificación , Retinitis por Citomegalovirus/tratamiento farmacológico , Farmacorresistencia Microbiana , Glicina/genética , Humanos , Serina/genéticaAsunto(s)
Adenoviridae/inmunología , Antígenos de Neoplasias , Antígenos Virales , ADN/metabolismo , Antígenos de Neoplasias/aislamiento & purificación , Antígenos Virales/aislamiento & purificación , Sitios de Unión , Línea Celular , Cromatografía de Afinidad , Peso Molecular , Proteínas Virales/metabolismoAsunto(s)
Antivirales/farmacología , Citomegalovirus/efectos de los fármacos , Farmacorresistencia Microbiana , VIH-1/efectos de los fármacos , Herpesvirus Humano 3/efectos de los fármacos , Humanos , Virus de la Influenza A/efectos de los fármacos , Pruebas de Sensibilidad Microbiana , Simplexvirus/efectos de los fármacosAsunto(s)
Antivirales/farmacología , Citomegalovirus/efectos de los fármacos , Ganciclovir/farmacología , Citomegalovirus/enzimología , Citomegalovirus/aislamiento & purificación , Infecciones por Citomegalovirus/microbiología , ADN Polimerasa II/antagonistas & inhibidores , Farmacorresistencia Microbiana , Células HeLa/enzimología , Humanos , CinéticaRESUMEN
The in vitro susceptibility of five strains of varicella-zoster virus to acyclovir was examined by the plaque-reduction method in human diploid lung cells. The 50% effective doses of acyclovir ranged from 2.06 microM to 6.28 microM in a 7-day assay, with a mean of 3.65 microM. Irreversible inhibition of plaque formtation was achieved by drug doses exceeding the 50% effective dose for plaque reduction but nontoxic to the cells. Studies on the relative in vitro susceptibility of varicella-zoster virus and herpes simplex virus types 1 and 2 to acyclovir suggested that varicella-zoster virus is two- to eightfold less susceptible to the drug. The antiviral potency of acyclovir for varicella-zoster virus in vitro was compared with that of several other nucleoside analogs. Analysis of the metabolism of acyclovir in varicella-zoster virus-infected WI-38 cells revealed that, as with herpes simplex virus types 1 and 2, the formation of the triphosphate forms of the drug is specific to viral infection.
Asunto(s)
Antivirales/farmacología , Guanina/análogos & derivados , Herpesvirus Humano 3/efectos de los fármacos , Aciclovir , Guanina/farmacología , Nucleótidos/metabolismo , Simplexvirus/efectos de los fármacos , Ensayo de Placa ViralRESUMEN
In the past 4 years, interest in drug-resistant herpesviruses has evolved from the realm of academic laboratory studies to that of great clinical importance. Recurrent and persistent infections due to the herpes simplex viruses, varicella-zoster virus, and human cytomegalovirus have been an unwelcome consequence of immunosuppression in graft recipients, cancer patients, and those suffering from AIDS. Treatment of these infections with the available antiviral drugs, such as acyclovir, ganciclovir, and foscarnet, has resulted in both clinical benefit and the emergence of drug-resistant variants. In addition, the role of Epstein-Barr virus is being clarified for an array of disease syndromes, and therapeutic approaches are beginning to emerge. In the present review, the emergence and clinical importance of drug resistance among the herpesviruses have been explored. Furthermore, particular attention has been focused on our understanding of the mechanisms of drug resistance and how that understanding will guide us in the development of more effective antiviral drugs and drug usage.